• Debt and leverage: Sun Pharma will operate at a net debt-to-EBITDA ratio of 2.3 times post-transaction, with management expressing confidence in repaying and reducing debt swiftly based on future cash flows.
• Vertical growth plans: Organon's stagnant revenue will be addressed by in-licensing late-stage innovative assets in women's health, launching line extensions and new formulations for established brands (which contribute 50–51% of revenue), and expanding its 7th-ranked biosimilars portfolio.
• Biosimilar expansion strategy: The company is pursuing global biosimilar opportunities via in-licensing rather than 6–8 year internal development cycles, driven by improved regulatory clarity regarding substitution and interchangeability as well as reduced clinical trial requirements.
• Debt refinancing structure: Organon carries approximately $8.5 billion in gross debt and nearly $900 million in cash; Sun Pharma intends to refinance net debt by exploring a bond swap with existing bondholders and issuing fresh debt for the remainder.
• China innovation access: Sun Pharma plans to leverage Organon’s existing infrastructure to access China's burgeoning pipeline of innovative biologics and small molecules, particularly across oncology and cardiology.